SCHEMBL737340

SCHEMBL737340

C[N+](C)(C)CC(N)OP(=O)([O-])O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
LMNA P02545 2/20 0.34
CHRM2 P08172 2/20 0.34
CHRM4 P08173 2/20 0.34
CHRM1 P11229 2/20 0.34
TSHR P16473 2/20 0.34
CHRM5 P08912 1/20 0.34
CHRM3 P20309 1/20 0.34
CYP2C9 P11712 1/20 0.34
MAPT P10636 2/20 0.33
SLC22A16 Q86VW1 1/20 0.32
TBXA2R P21731 1/20 0.31
LAP3 P28838 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
HRH1 P35367 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
METAP1 P53582 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8911564 0.78 SLC22A16 (0.38) CPT2CPT1ALMNACHRM2CHRM4
SCHEMBL2553127 0.76 SLC22A16 (0.32) CPT2CPT1ALMNACHRM2CHRM4
SCHEMBL11347712 0.76 SLC22A16 (0.32) CPT2CPT1ALMNACHRM2CHRM4
SCHEMBL192296 0.74 MEN1 (0.39) LMNATSHRCYP2C9MAPTSLC22A16
SCHEMBL14739986 0.74 GABBR2 (0.36) CPT2CPT1ALMNACHRM2CHRM4
SCHEMBL8910736 0.73 LAP3 (0.37) CPT2CPT1ALMNACHRM2CHRM4
SCHEMBL14739090 0.72 MEN1 (0.35) LMNATSHRCYP2C9MAPTMEN1
SCHEMBL1692410 0.72 MEN1 (0.37) LMNATSHRCYP2C9MAPTMEN1
SCHEMBL29869153 0.72 MEN1 (0.33) CPT2CPT1ASLC22A16MEN1CYP1A2
SCHEMBL3503898 0.71 MEN1 (0.34) LMNAMEN1CYP1A2HRH1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100040712-A1 THROAT SPRAY CNS, INC. 2010-02-18 US claimed
EP-2015761-A4 METHODS AND COMPOSITION FOR TREATING SORE THROAT NAVEH PHARMA 1996 LTD (IL) 2009-07-29 EP claimed
EP-2015761-A2 METHODS AND COMPOSITION FOR TREATING SORE THROAT Naveh Pharma (1996) Ltd. (IL) 2009-01-21 EP claimed
US-20080124411-A1 nasal strip; and an orally administered composition comprising a tissue-firming agent, a tissue-soothing agent, a tissue lubricant, and an expectorant; for combating snoring CNS, INC. (US) 2008-05-29 US claimed
WO-2007110871-A2 METHODS AND COMPOSITION FOR TREATING SORE THROAT NAVEH PHARMA (1996) LTD. (IL) 2007-10-04 WO claimed
US-20060057227-A1 Throat spray CNS, INC. 2006-03-16 US claimed
EP-1513481-A2 THROAT SPRAY CNS, Inc. (US) 2005-03-16 EP claimed
WO-2003070178-A2 THROAT SPRAY CNS, INC. (US) 2003-08-28 WO claimed
US-8138200-B2 Compositions and methods for double-targeting virus infections and targeting cancer cells WAKE FOREST UNIVERSITY (US) 2012-03-20 US disclosed
US-20100184718-A1 Compositions and Methods for Double-Targeting Virus Infections and Targeting Cancer Cells WAKE FOREST UNIVERSITY 2010-07-22 US disclosed
US-20100040712-A1 THROAT SPRAY CNS, INC. 2010-02-18 US disclosed
US-7638528-B2 Compositions and methods for targeting cancer cells WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE (US) 2009-12-29 US disclosed
EP-2015761-A4 METHODS AND COMPOSITION FOR TREATING SORE THROAT NAVEH PHARMA 1996 LTD (IL) 2009-07-29 EP disclosed
EP-2015761-A2 METHODS AND COMPOSITION FOR TREATING SORE THROAT Naveh Pharma (1996) Ltd. (IL) 2009-01-21 EP disclosed
US-20020082242-A1 Compositions and methods of double-targeting virus infections and cancer cells WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE 2002-06-27 US disclosed
US-6329352-B1 APPLYING PULMONARY ALVEOLAR SURFACTANT BEFORE SLEEP WISCONSIN ALUMNI RESEARCH FOUNDATION 2001-12-11 US disclosed
WO-2001034614-A2 COMPOSITIONS AND METHODS FOR DOUBLE-TARGETING VIRUS INFECTIONS AND TARGETING CANCER CELLS WAKE FOREST UNIVERSITY (US) 2001-05-17 WO disclosed
EP-1009411-A1 METHOD AND COMPOSITION FOR TREATING SLEEP APNEA WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2000-06-21 EP disclosed
US-5958902-A APPLYING A PULMONARY ALVEOLAR SURFACTANT PREPARATION IN A PHARMACOLOGICALLY EFFECTIVE DOSE TO THE POSTERIOR PHARYNGEAL REGION OF A PATIENT PRIOR TO A PERIOD OF SLEEP. WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-09-28 US disclosed
WO-1998046245-A1 METHOD AND COMPOSITION FOR TREATING SLEEP APNEA WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082242-A1 Compositions and methods of double-targeting virus infections and cancer cells PHOSPHO1, PIGS, SMPD1 CPT2 1161/4885CPT1A 985/4885LMNA 870/4885
US-20100184718-A1 Compositions and Methods for Double-Targeting Virus Infections and Targeting Cancer Cells PHOSPHO1, PIGS, SMPD1 CPT2 1013/4885CPT1A 1050/4885LMNA 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.